NEW YORK, Nov. 30—Abbott Laboratories concluded its acquisition of Vysis as scheduled at midnight on November 29.

The pharmaceutical company commenced a cash tender offer on Oct. 31 to purchase all outstanding shares of the genomics-based disease management company. 

As a final step, remaining Vysis shareholders will receive the same $30.50 per share cash price as paid in the tender offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.